Innate Pharma
FREURInnate Pharma (PA:IPH) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- innate-pharma.com
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- MARSEILLE, France
- Management
- Jonathan E. Dickinson
- Employees
- 120
- Founded
- 1999
- Shares outstanding
- 111.7 M
- Free float
- 70.45 M
- Market cap
- 146.33 M EUR
- Insiders
- 17.46%
- Institutions
- 10.86%
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- Legal form
- K65D
- ISIN
- FR0010331421
- LEI
- 9695002Y8420ZB8HJE29
- P/E
- loss
- FCF
- −52.9 M EUR
- Debt
- ?
- Earnings and FCF — for the 12 months to 31.12.2025 (the company's latest report).
Description
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
News this week
Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| ETF Series Solutions-Ran… | 0.08% | 72 695 | 2025-02-28 |
| Lion Point Capital, LP | 0.07% | 81 151 | 2026-06-30 |
| Morgan Stanley | 0.04% | 43 524 | 2026-06-30 |
| Smartharvest Portfolios,… | 0.02% | 23 750 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.02% | 23 277 | 2026-01-31 |
| Xtx Topco Ltd | 0.01% | 15 130 | 2026-06-30 |
| Citadel Advisors Llc | 0.01% | 12 441 | 2026-06-30 |
| Jane Street Group, LLC | 0.01% | 10 310 | 2026-06-30 |
| Rhumbline Advisers | 0% | 4 719 | 2026-06-30 |
| UBS Group AG | 0% | 1 363 | 2026-06-30 |
| Farther Finance Advisors… | 0% | 21 | 2026-06-30 |
| Gamma Investing LLC | 0% | 9 | 2026-06-30 |
